Phase II Study of Combination Chemotherapy with Biweekly Cetuximab and Irinotecan for Pre-treated Metastatic Colorectal Cancer Harboring Wild-type KRAS

被引：4

作者：

Shitara, Kohei ^{[1
]}

Yokota, Tomoya

Takahari, Daisuke

Shibata, Takashi

Ura, Takashi

Komatsu, Yoshito ^{[2
,3
]}

Yuki, Satoshi ^{[2
]}

Yoshida, Motoki ^{[4
]}

Takiuchi, Hiroya ^{[4
]}

Utsunomiya, Setsuo ^{[5
]}

Yatabe, Yasushi ^{[6
]}

Muro, Kei

机构：

[1] Aichi Canc Ctr Hosp, Dept Clin Oncol, Chikusa Ku, Aichi 4648681, Japan

[2] Hokkaido Univ, Grad Sch Med, Dept Gastroenterol, Sapporo, Hokkaido 060, Japan

[3] Hokkaido Univ Hosp, Ctr Canc, Dept Canc Chemotherapy, Sapporo, Hokkaido, Japan

[4] Osaka Med Coll, Ctr Canc Chemotherapy, Osaka, Japan

[5] Nagoya Kyoritsu Hosp, Dept Gastroenterol, Nagoya, Aichi, Japan

[6] Aichi Canc Ctr, Dept Pathol & Mol Diagnost, Aichi, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 40卷 / 07期

关键词：

colorectal cancer; chemotherapy; cetuximab; irinotecan; PLUS IRINOTECAN; MUTATION; OXALIPLATIN;

D O I：

10.1093/jjco/hyq026

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Standard weekly cetuximab and irinotecan is an effective regimen in heavily pre-treated patients with metastatic colorectal cancer. The aim of this study is to prospectively evaluate the efficacy of combination chemotherapy with biweekly cetuximab and irinotecan in patients with pre-treated metastatic colorectal cancer harboring wild-type KRAS. A total of 30 patients will be enrolled at four medical institutions. The primary endpoint is response rate. The secondary endpoints include adverse events, progression-free survival and overall survival. The pharmacokinetics of cetuximab will also be evaluated in five patients.

引用

页码：699 / 701

页数：3

共 15 条

[1]

[Anonymous], NCCN CLIN PRACT GUID

[2] Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].

Benvenuti, Silvia ;

Sartore-Bianchi, Andrea ;

Di Nicolantonio, Federica ;

Zanon, Carlo ;

Moroni, Mauro ;

Veronese, Silvio ;

Siena, Salvatore ;

Bardelli, Alberto .

CANCER RESEARCH, 2007, 67 (06) :2643-2648

[3] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[4] KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab [J].

De Roock, W. ;

Piessevaux, H. ;

De Schutter, J. ;

Janssens, M. ;

De Hertogh, G. ;

Personeni, N. ;

Biesmans, B. ;

Van Laethem, J. -L. ;

Peeters, M. ;

Humblet, Y. ;

Van Cutsem, E. ;

Tejpar, S. .

ANNALS OF ONCOLOGY, 2008, 19 (03) :508-515

[5] Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy [J].

Di Fiore, F. ;

Blanchard, F. ;

Charbonnier, F. ;

Le Pessot, F. ;

Lamy, A. ;

Galais, M. P. ;

Bastit, L. ;

Killian, A. ;

Sesboue, R. ;

Tuech, J. J. ;

Queuniet, A. M. ;

Paillot, B. ;

Sabourin, J. C. ;

Michot, F. ;

Michel, P. ;

Frebourg, T. .

BRITISH JOURNAL OF CANCER, 2007, 96 (08) :1166-1169

[6] Cetuximab for the treatment of colorectal cancer [J].

Jonker, Derek J. ;

O'Callaghan, Chris J. ;

Karapetis, Christos S. ;

Zalcberg, John R. ;

Tu, Dongsheng ;

Au, Heather-Jane ;

Berry, Scott R. ;

Krahn, Marianne ;

Price, Timothy ;

Simes, R. John ;

Tebbutt, Niall C. ;

van Hazel, Guy ;

Wierzbicki, Rafal ;

Langer, Christiane ;

Moore, Malcolm J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (20) :2040-2048

[7] K-ras mutations and benefit from cetuximab in advanced colorectal cancer [J].

Karapetis, Christos S. ;

Khambata-Ford, Shirin ;

Jonker, Derek J. ;

O'Callaghan, Chris J. ;

Tu, Dongsheng ;

Tebbutt, Niall C. ;

Simes, R. John ;

Chalchal, Haji ;

Shapiro, Jeremy D. ;

Robitaille, Sonia ;

Price, Timothy J. ;

Shepherd, Lois ;

Au, Heather-Jane ;

Langer, Christiane ;

Moore, Malcolm J. ;

Zalcberg, John R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (17) :1757-1765

[8] KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab [J].

Lievre, Astrid ;

Bachet, Jean-Baptiste ;

Boige, Valerie ;

Cayre, Anne ;

Le Corre, Delphine ;

Buc, Emmanuel ;

Ychou, Marc ;

Bouche, Olivier ;

Landi, Bruno ;

Louvet, Christophe ;

Andre, Thierry ;

Bibeau, Frederic ;

Diebold, Marie-Daniele ;

Rougier, Philippe ;

Ducreux, Michel ;

Tomasic, Gorana ;

Emile, Jean-Francois ;

Penault-Llorca, Frederique ;

Laurent-Puig, Pierre .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) :374-379

[9] Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy:: results of a phase II single institution trial [J].

Martin-Martorell, P. ;

Rosello, S. ;

Rodriguez-Braun, E. ;

Chirivella, I. ;

Bosch, A. ;

Cervantes, A. .

BRITISH JOURNAL OF CANCER, 2008, 99 (03) :455-458

[10] Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil [J].

Pfeiffer, P. ;

Nielsen, D. ;

Bjerregaard, J. ;

Qvortrup, C. ;

Yilmaz, M. ;

Jensen, B. .

ANNALS OF ONCOLOGY, 2008, 19 (06) :1141-1145

← 1 2 →